Dear Dr. Muzina and Dr. Schlott,
The New England Endocrine Alliance is comprised of over 450 members of the endocrine community. We are committed to providing the best possible care to our patients with diabetes and other endocrine conditions. We treat many patients with male hypogonadism with testosterone therapy.
We recently have had patients with male hypogonadism on Wellsense insurance who have had difficulty with testosterone coverage. A recent patient with documented hypogonadism on long term testosterone therapy had a few gaps in his refill history and needed to have two low testosterone levels 3 months apart to have his testosterone therapy coverage resumed again. Disruption of testosterone replacement therapy leads to adverse clinical impacts, including the development of low testosterone levels with clinical signs and symptoms of hypogonadism.
VIEW FULL LETTER
